Development Payments. As an inducement for and in consideration of the agreement of Biomatrix to actively participate in and support the Development Program as set forth in Section 6 of the U.S. Agreement, Wyeth hereby agrees to make the following non-refundable payments to Biomatrix:
Development Payments. 6.2.3. 3112 Product Inovio shall be responsible for operational execution of the 3112 Development Plan in cooperation with MedImmune via the JCSC through the Transition Period. The 3112 Development Plan shall mean the plan for conduct of ongoing and planned 3112 Trials (XXX-000, XXX-000 and HPV-007) and include the budget which is current and agreed as of the Effective Date. [XXXXXXX]. After the Transition Period, MedImmune shall be solely responsible for the Development, Manufacturing and Commercialization, including operational execution and financial responsibility thereof, of the 3112 Product in the 3112 Field in the Territory.
Development Payments. In consideration of the development efforts of Microgenics under the Research Program, Achaogen shall pay to Microgenics the following one-time payments upon the occurrence of the corresponding events:
Development Payments. 4.1 In consideration of the rights granted to Neurocrine in Article 2, herein, Neurocrine shall pay to DOV a licensing fee of $5,000 upon the execution of this Agreement.
Development Payments. Miles agrees to pay Onyx the amounts (“Development Payments”) specified below. Such payments will occur with respect to each Development Compound during the Clinical Development Period under the management of the JRDC as long as the Co-Development continues. No payments under this Section shall be due for independent development pursuant to Section 12.4. Miles shall make the following Development Payments:
Development Payments. 1. On the later of October 1, 1996 or the Effective Date, ReSound shall pay $500,000 to AL2. From January 1, 1997 (for ReSound) and from or immediately after the Effective Date (for Danavox), in each case through the date which is two (2) years from the Effective Date, each of Danavox and ReSound shall pay a total of $5,981,000 to AL2 under this Agreement, to be paid at such times and in such amounts and for the purposes as set forth in the Budget attached hereto as EXHIBIT F, or as otherwise determined by the General Partner of AL2 (the "Initial Payments"). All such amounts paid by ReSound and Danavox shall be paid on a proportional basis as between the two entities.
Development Payments. In consideration of Palatin’s performance under Section 4.1, AMAG shall pay Palatin the amounts set forth below within […***…] following the first occurrence of each event described below for the first Product to achieve such event (each, a “Development Payment”).
Development Payments. Pfizer will pay BioNTech RNA the one-off amounts set forth below within 60 days following the first occurrence of each event described below for the first Candidate or Product (as applicable) Covered by a Valid Claim in the applicable country of Development or Commercialization in the Territory to achieve such event (each, a “Development Payment”).
Development Payments. In consideration for ALZA's work on the Program, Durect shall pay to ALZA its Development Costs, provided that Durect shall not be obligated to pay Development Costs in excess of those provided for in approved Work Plans and Cost Estimates, and ALZA shall not be obligated to perform work which would result in Development Costs exceeding such approved Cost Estimates.
Development Payments. PRI shall pay to ACT its Development Supply Costs as based on the number of FTEs ordinarily and necessarily required for the supply of Collaboration Product for clinical trials. PRI will pay ACT for all other developmental work required or requested by PRI based on the number of FTEs ordinarily and necessarily required for THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS BRACKETED AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. execution of such work as approved by PRI. Payments by PRI to ACT hereunder shall be made after the Effective Date, within 30 days of receiving an invoice for expenses owed from previous work or clinical supply Collaboration Product delivered. Cost overruns where the actual Development Supply Costs exceeds the estimated Development Supply Costs as approved in the Research Plan of up to [X ] are expected by the Parties. Cost overruns exceeding [X] are to the account of ACT except that PRI, in its sole discretion, may choose to pay such overruns where circumstances warrant. ACT will notify PRI of cost overruns of which it becomes aware within a reasonable time period. The purchase of any item reasonably required by ACT to supply Collaboration Product for clinical trials shall be ACT's obligation and responsibility.
